NeoStem Announces Proposed Public Offering of Common Stock
May 27 2015 - 3:01PM
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced
today that it is commencing an underwritten public offering of its
common stock. The Company intends to use the net proceeds from this
offering for working capital, including research and development of
cell therapeutic product candidates, especially its lead
immuno-oncology program, NBS20, expansion of business units,
strategic transactions and other general corporate purposes. The
offering is subject to market conditions and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Aegis Capital Corp. is acting as sole book-running
manager for the offering. The offering is being made pursuant
to a shelf registration statement that the Company previously filed
with the Securities and Exchange Commission (the "SEC") and which
became effective on October 3, 2012. A preliminary prospectus
supplement and accompanying prospectus relating to the offering
will be filed with the SEC and will be available on the SEC's
website located at www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
this offering may be obtained, when available, from Aegis Capital
Corp., 810 7th Avenue, 18th Floor, New York, NY 10019 or via
telephone at 212-813-1010 or email:
prospectus@aegiscap.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation
and enhancement of human health globally through the development of
novel cell-based individualized medicine therapeutics that prevent,
treat or cure disease. The Company is developing therapies based on
three platform technologies (immuno-oncology, ischemic repair and
immunomodulation) with a focus on its lead, Phase
3 clinical program for NBS20 in immuno-oncology.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management's current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. Forward-looking statements include
statements herein with respect to the timing and success of the
proposed public offering. The Company's actual results could differ
materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause
future results to materially differ from the recent results or
those projected in forward-looking statements include, among
others, the uncertainties related to market conditions, the
completion of the public offering on the anticipated terms or at
all, the final terms of the proposed offering, and the satisfaction
of customary closing conditions related to the proposed public
offering. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to the
business of the Company in general, see the factors described under
the heading, "Item 1A. Risk Factors" in the Company's Annual
Report on Form 10-K filed with the SEC on March 2, 2015 and those
described in the Company's other periodic filings with the SEC. The
Company undertakes no obligation to update or revise any
forward-looking statements.
CONTACT: NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jul 2023 to Jul 2024